This guideline has been initiated by the task force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus‐based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue‐bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10–25% of patients laminin 332 is recognized. In 25–30% of MMP patients with anti‐laminin 332 reactivity, malignancies have been associated. As first‐line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first‐line regimens. Additional recommendations are given, tailored to treatment of single‐site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high‐quality randomized controlled trials.

This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task Force for Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology (EADV) with a contribution of physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based guideline encompassing a systematic review of the literature until June 2019 in the MEDLINE and EMBASE databases. This first part covers methodology, the clinical definition of MMP, epidemiology, MMP subtypes, immunopathological characteristics, disease assessment and outcome scores. MMP describes a group of autoimmune skin and mucous membrane blistering diseases, characterized † Both authors contributed equally.

This study has validated the ODSS for the assessment of oral PV. It has shown superior inter- and intraobserver reliability to PDAI, ABSIS and PGA and is quick to perform.

Aim:The study compared pulp temperature rise during polymerization of resin-based composites (RBCs) using halogen and LED light-curing units (LCUs). Methods and Materials:A total of 32 teeth extracted from patients aged 11-18 years were used in the study. Thermocouples placed on the roof of the pulp chamber using a novel 'split-tooth' method. In Group 1 a halogen LCU with a light intensity of 450 mWcm -2 was used and in Group 2, an LED LCU with a light intensity of 1100 mWcm -2 was used. The teeth were placed in a water bath with the temperature regulated until both the pulp temperature and the ambient temperature were stable at 37ºC. Continuous temperature records were made via a data logger and computer. The increase in temperature from baseline to maximum was calculated for each specimen during the curing of both the bonding agent and the RBC. Results:The rise in pulp temperature was significantly higher with the LED LCU than with the halogen LCU for bonding and RBC curing (p<0.05). The major rise in temperature occured during the curing of the bonding agent. During the curing of the RBC, rises were smaller. Conclusions:Curing of bonding agents should be done with low intensity light and high intensity used only for curing RBC regardless of whether LED or halogen LCUs are used. Abstract© Seer Publishing